Corglicard

Corglicard: description, use, contraindications

Korglykard is a cardiac glycoside produced in Ukraine at the pilot plant of the State Scientific Center for Clinical Medicine Ukrmedprom. It contains a sum of glycosides from lily of the valley leaves and is used for the treatment of acute and chronic circulatory failure of degrees II and III, cardiac decompensation complicated by the tachysystolic form of atrial fibrillation, as well as to relieve attacks of paroxysmal tachycardia.

Like other cardiac glycosides, Corglicard improves heart function, increasing the strength and rhythm of its contractions. It also reduces the workload on the heart and improves blood circulation in the body.

However, Korglicard also has contraindications. It should not be used in cases of sudden organic changes in the heart and blood vessels, acute myocarditis, endocarditis and severe cardiosclerosis. Caution is also necessary in case of thyrotoxicosis and atrial extrasystole due to the possibility of their transition to atrial fibrillation.

There is no data on side effects, interactions or overdose of Corglikard. However, as with the use of any medicine, it is necessary to monitor the patient’s condition and, if necessary, consult a doctor.

In general, Corglicard is an effective medicine for the treatment of cardiovascular diseases and can be recommended for appropriate indications. However, before using it, you should consult your doctor and analyze possible risks and contraindications.